Brodalumab

Active Crohn's disease, clinically significant active infections (e.g. active TB).

Patient with history of chronic or recurrent infection; history of depression and/or suicidal ideation or behaviour; inflammatory bowel disease. Avoid concomitant use with live vaccines. Pregnancy and lactation.

Significant: Suicidal ideation and behaviour; severe eczematous eruptions (e.g. atopic dermatitis-like eruptions); increased risk of infections; reactivation or worsening of Crohn's disease and ulcerative colitis. Rarely, anaphylactic reactions.
Gastrointestinal disorders: Diarrhoea, nausea.
General disorders and administration site conditions: Fatigue, inj site reactions (e.g. erythema, pain, pruritus, bruising, haemorrhage).
Infections and infestations: Influenza, tinea infections (e.g. tinea pedis, tinea versicolor, tinea cruris).
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Headache.
Respiratory, thoracic and mediastinal disorders: Oropharyngeal pain.

Women of childbearing potential must use effective method of contraception during therapy and for 12 weeks after stopping the treatment.

Evaluate for TB infection, current or latent infection, malignancy (particularly skin cancer), and lymphadenopathy before treatment initiation. Monitor CBC and LFTs every 3-6 months or as clinically indicated. Assess for signs and symptoms of infection and active TB (during and after treatment); new or worsening depression, suicidal ideation or behaviour, and inflammatory bowel disease.

May diminish the therapeutic effect or enhance the adverse effects of live vaccines.

Description:
Mechanism of Action: Brodalumab is a recombinant human immunoglobulin G₂ monoclonal antibody. It antagonises interleukin-17 receptor A (IL-17RA) pathway by selectively binding to IL-17RA, thus inhibiting its interaction with the pro-inflammatory cytokines IL-17A, IL-17C, IL-17F, IL-17A/F heterodimer and IL-17E. This action prevents cytokine-induced responses, including the release of pro-inflammatory cytokines and chemokines.
Onset: After 12 weeks.
Pharmacokinetics:
Absorption: Bioavailability: Approx 55%. Time to peak plasma concentration: Approx 3 days.
Distribution: Volume of distribution: 8.9 ± 9.4 L.
Metabolism: Undergoes degradation via catabolic pathways into small peptides and amino acids.

Store between 2-8°C. Do not freeze or shake. If necessary, may be stored at room temperature (<25°C) for a single period of up to 14 days. After removal from the refrigerator, it should be used within 14 days or discarded. Protect from light and extreme heat.

Immunosuppressants

L04AC12 - brodalumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Brayfield A, Cadart C (eds). Brodalumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/08/2025.

Brodalumab. UpToDate Lexidrug, AHFS DI (Adult and Pediatric) Online. American Society of Health-System Pharmacists, Inc. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 06/08/2025.

Brodalumab. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 06/08/2025.

Joint Formulary Committee. Brodalumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/08/2025.

Kyntheum 210 mg Solution for Injection in Pre-filled Syringe (LEO Pharma A/S). MHRA. https://products.mhra.gov.uk. Accessed 06/08/2025.

Lumicef Subcutaneous Injection 210 mg Syringe (DKSH Malaysia Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 06/08/2025.

Siliq Injection (Bausch Health US LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 06/08/2025.